DriverPower identified four histone genes as driver candidates in the pan-cancer cohort, two of which were absent from CGC or PCAWG-consensus: the 5′-UTR of HIST1H2AC and HIST1H2BD. Previous studies have shown that the protein levels of the replication-dependent histone H2A variant HIST1H2AC (encoding histone H2A type 1-C) is decreased in chronic lymphocytic leukaemia patients and bladder cancer cells45,46, and the siRNA knockdown of HIST1H2AC increases cell proliferation and promote oncogenesis46. This evidence concerns the gene H2AC6 and urinary bladder cancer.